Tilray’s stock is flying higher… again. But after years of false starts, net losses, and wild dreams, is this the real lift-off—or just another high followed by a low? Find out what’s cooking with Tilray’s drinks, cannabis brands, AI strategy, and why its reverse stock split is both approved and… on pause.

Read entire article

Hedge fund legend Stanley Druckenmiller just upped his stake in TEVA by 65%—and he’s not alone. With 9 straight quarters of growth, rising biosimilar momentum, and a “Pivot to Growth” strategy in motion, Teva might finally be ready for its rerating. We still like the sandals, but the stock may be worth more than a hike.

Read entire article

Wildfires can’t scorch this Swiss insurance juggernaut. With Buffett, big buys, and billion-dollar buybacks, Chubb may be the steadiest hot stock around. 🧯📈

Read entire article